Extension of Time to File SOU

ABRYSVO

Pfizer Inc.

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 97018602
LAW OFFICE ASSIGNED LAW OFFICE 119
MARK SECTION
MARK ABRYSVO (see, http://uspto.report/TM/97018602/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT ABRYSVO
OWNER SECTION (current)
NAME Pfizer Inc.
MAILING ADDRESS 235 East 42nd Street
CITY New York
STATE New York
ZIP/POSTAL CODE 10017
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 212-733-0086
EMAIL XXXX
OWNER SECTION (proposed)
NAME Pfizer Inc.
MAILING ADDRESS 235 East 42nd Street
CITY New York
STATE New York
ZIP/POSTAL CODE 10017
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 212-733-0086
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME RICHARD A. FRIEDMAN
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) docketingipnyo@pfizer.com
CORRESPONDENCE INFORMATION (proposed)
NAME Richard A. Friedman
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) docketingipnyo@pfizer.com
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 08/30/2022
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /RAF/
SIGNATORY'S NAME Richard A. Friedman
SIGNATORY'S POSITION Assistant General Counsel
DATE SIGNED 01/05/2023
SIGNATORY'S PHONE NUMBER 212-733-0086
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Thu Jan 05 16:04:23 ET 2023
TEAS STAMP USPTO/ESU-XXX.XXX.XX.X-20
230105160423939363-970186
02-850f9914ad7dd846c888a8
96af53e53761edb968bef8cec
410be97479bf8251f-DA-0423
3223-20230105144328061631



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: ABRYSVO (see, http://uspto.report/TM/97018602/mark.png)
SERIAL NUMBER: 97018602

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Pfizer Inc., having an address of
      235 East 42nd Street
      New York, New York 10017
      United States
      Phone: 212-733-0086
      Email: XXXX
Proposed: Pfizer Inc., having an address of
      235 East 42nd Street
      New York, New York 10017
      United States
      Phone: 212-733-0086
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 08/30/2022.

For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      RICHARD A. FRIEDMAN
      PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): docketingipnyo@pfizer.com

Correspondence Information (proposed):
      Richard A. Friedman
      PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): docketingipnyo@pfizer.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /RAF/      Date Signed: 01/05/2023
Signatory's Name: Richard A. Friedman
Signatory's Position: Assistant General Counsel
Signatory's Phone: 212-733-0086
Signature method: Sent to third party for signature

PAYMENT: 97018602
PAYMENT DATE: 01/05/2023

Serial Number: 97018602
Internet Transmission Date: Thu Jan 05 16:04:23 ET 2023
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.X-20230105160423939
363-97018602-850f9914ad7dd846c888a896af5
3e53761edb968bef8cec410be97479bf8251f-DA
-04233223-20230105144328061631




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed